Home > Oncology > ELCC 2019 > Trial Data: Early Stage Lung Cancer > Genomic and immune profiling

Genomic and immune profiling

Presented By
Dr Ke-Zhong Chen, Peking University People’s Hospital, Beijing, China
ELCC 2019
Recently, neoadjuvant targeted therapy and immunotherapy have shown a promising clinical effect for localised stage NSCLC. However, the relation between genomic and immune profiling has been poorly delineated. Dr Ke-Zhong Chen (Peking University People’s Hospital, Beijing, China) reported the first prospective study integrating genomic variation and profiling of the T cell receptor repertoire in localised surgical lung adenocarcinoma [4]. In 100 enrolled patients, EGFR (65.4%), TP53 (36.5%), and KRAS (11.5%) were most frequently mutated. Change in T cell receptor repertoire and tumour mutational burden were found to be dependent on invasiveness of tumour type and to have a broad range in EGFR mutation. Invited discussant Dr Anne-Marie Dingemans (University Hospital Maastricht, the Netherlands) applauded the investigators on their data. “In 1 year, tissue and plasma samples of more than 100 patients was collected. ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on